Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Bausch + Lomb Corporation ( (BLCO) ) is now available.
Bausch + Lomb Corporation announced that its senior leadership team, including Chairman and CEO Brent Saunders, CFO Sam Eldessouky and Chief Medical Officer and Head of R&D Yehia Hashad, will deliver a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Jan. 12, 2026. The appearance at this high-profile investor event, which will be accessible via live webcast and archived on the company’s investor relations website, provides Bausch + Lomb with a platform to highlight its strategy, innovation agenda and financial narrative to the broader healthcare investment community, potentially reinforcing its positioning in the global eye health market.
The most recent analyst rating on (BLCO) stock is a Hold with a $17.50 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.
Spark’s Take on BLCO Stock
According to Spark, TipRanks’ AI Analyst, BLCO is a Neutral.
Bausch + Lomb’s stock score is driven by strong revenue growth and positive technical indicators. However, profitability challenges and a negative P/E ratio weigh on the valuation. The earnings call highlights strategic resilience, but operational efficiency improvements are needed.
To see Spark’s full report on BLCO stock, click here.
More about Bausch + Lomb Corporation
Bausch + Lomb Corporation is a global eye health company focused on improving vision through a broad portfolio that includes contact lenses, prescription eye-care products, over-the-counter eye health solutions and surgical devices. With a nearly 200-year history, the company emphasizes innovation and advancing standards of care for patients and customers worldwide.
Average Trading Volume: 472,182
Technical Sentiment Signal: Buy
Current Market Cap: $6.01B
Learn more about BLCO stock on TipRanks’ Stock Analysis page.